Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 1Hypertension 1Hot Flashes 1Diabetes Mellitus 1Depressive Disorder, Major 1Depression 1Cardiovascular Diseases 1Breast Neoplasms 1

Interventions

Therapeutics 31Psychiatric Rehabilitation 27Surveys and Questionnaires 15Cognitive Behavioral Therapy 12Early Intervention, Educational 10Psilocybin 9Ketamine 9Methods 8Saline Solution 7Yoga 6Mindfulness-Based Cognitive Therapy 6Interviews as Topic 6Esketamine 6Counseling 6Psychosocial Intervention 5Mindfulness 5Methylphenidate 5Escitalopram 5Educational Status 5Behavior Therapy 5Acupuncture Therapy 5Palliative Care 4Exercise Therapy 4Exercise 4Control Groups 4Caregivers 4Standard of Care 3Psychotherapy 3Niacin 3Mindfulness-Based Stress Reduction 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Depression × Desvenlafaxine Succinate × Clear all
NCT01803711 2017-12-27

Omega 3 FA Supplements as Augmentation in the Treatment of Depression

UConn Health

Phase 2/3 Terminated
6 enrolled 4 charts

Cardiovascular Diseases, Depression, Depressive Disorder, Major, Diabetes Mellitus, Hypertension, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡